Investor Conference – BRIM Biotechnology, Inc.

News

BRIM Biotechnology Advances Four New Drugs, Adopting Two Key Strategies for Precision Medicine

Pre-IPO Performance Briefing Scheduled for November 14

BRIM closes a $45.8 million rights issue early to accelerate its pipeline of regenerative peptides

Taiwan has ambitions to make biotech ‘second industry’ after semi-conductors

BRIM plans to launch a new funding round to accelerate late-stage clinical trial and initiate a new phase 2 trial for orphan drug BRM424 in the U.S

BRM421, a new drug for treating Dry Eye Disease, receives approval to proceed to Phase 2 clinical trials in China

BRIM submits US IND for BRM424 Phase 2 study treating neurotrophic keratitis

BRIM Biotechnology announces first patient enrollment in pivotal Phase 3 clinical trial of BRM421 for Dry Eye Disease

Novel regenerative peptide therapy for dry eye disease, BRM421, advances to Phase 3 clinical trials

BRIM Biotechnology strengthens leadership team in preparation for transformational year ahead

1 2 3 Next »